{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:05:05Z","timestamp":1779905105080,"version":"3.53.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00341299"],"award-info":[{"award-number":["RS-2024-00341299"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    <jats:italic>Mycobacterium avium<\/jats:italic>\n                    complex pulmonary disease (MAC-PD) requires prolonged multidrug therapy. However, treatment outcomes remain suboptimal due to limited antibiotic efficacy, disease chronicity, and frequent early treatment interruption (ETI). Despite its clinical significance, data on the prevalence, risk factors, and long-term outcomes of ETI remain limited. Therefore, this study aims to identify factors associated with ETI and its impact on mortality. A retrospective cohort study of 420 patients treated with MAC-PD was conducted between 2010 and 2023. Patients were categorized into ETI (treatment duration\u2009&lt;\u200912 months) and standard groups (treatment duration\u2009\u2265\u200912 months). Logistic regression was used to identify risk factors for ETI, whereas multivariate Cox proportional hazards regression was employed to evaluate factors associated with mortality. ETI occurred in 30% of patients. Low prognostic nutritional index (PNI) (adjusted odds ratio [aOR]: 0.92; 95% confidence Interval [CI]: 0.87\u20130.99) and grade 2 or higher adverse drug reactions (ADRs) (aOR: 5.65; 95% CI: 2.45\u201315.00) increased the risk of ETI. ETI was associated with higher mortality (adjusted hazard ratio: 2.86; 95% CI: 1.51\u20135.40). Additionally, low PNI scores indicated increased mortality risk. ETI is prevalent in MAC-PD and is strongly associated with ADRs and poor nutrition, both of which also predict higher long-term mortality. Early ADR monitoring and nutritional support are essential for improving treatment adherence and patient outcomes.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0350106","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:31:55Z","timestamp":1779903115000},"page":"e0350106","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early treatment interruption and nutritional status as predictors of mortality in Mycobacterium avium complex pulmonary disease"],"prefix":"10.1371","volume":"21","author":[{"given":"Hye Young","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngmok","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Yee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8818-6115","authenticated-orcid":true,"given":"A","family":"La Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7783-5271","authenticated-orcid":true,"given":"Young Ae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"4","key":"pone.0350106.ref001","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"CL Daley","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0350106.ref002","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"N Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0350106.ref003","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14787210.2020.1720650","article-title":"Antibiotic therapy success rate in pulmonary Mycobacterium avium complex: a systematic review and meta-analysis","volume":"18","author":"MJ Nasiri","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"pone.0350106.ref004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12931-024-02752-y","article-title":"Variables associated with antibiotic treatment tolerance in patients with Mycobacterium avium complex pulmonary disease","volume":"25","author":"M Marmor","year":"2024","journal-title":"Respir Res"},{"issue":"1","key":"pone.0350106.ref005","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s12879-022-07568-z","article-title":"Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system","volume":"22","author":"T Ozawa","year":"2022","journal-title":"BMC Infect Dis"},{"key":"pone.0350106.ref006","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/cid\/ciac788","article-title":"Treatment of nontuberculous mycobacterial pulmonary infection in the US bronchiectasis and NTM registry: treatment patterns, adverse events, and adherence to American Thoracic Society\/Infectious Disease Society of America treatment guidelines","volume":"76","author":"JH Ku","year":"2023","journal-title":"Clin Infect Dis"},{"key":"pone.0350106.ref007","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jgar.2020.01.004","article-title":"Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: a propensity score analysis","volume":"22","author":"YS Kwon","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"issue":"5","key":"pone.0350106.ref008","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.chest.2023.06.015","article-title":"Microbiological cure at treatment completion is associated with longer survival in patients with Mycobacterium avium complex pulmonary disease","volume":"164","author":"J-Y Kim","year":"2023","journal-title":"Chest"},{"issue":"9","key":"pone.0350106.ref009","article-title":"Treatment outcomes after discontinuation of ethambutol due to adverse events in Mycobacterium avium complex lung disease","volume":"35","author":"YS Kwon","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"5","key":"pone.0350106.ref010","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3390\/jcm9051315","article-title":"Long-term treatment outcome of progressive Mycobacterium avium complex pulmonary disease","volume":"9","author":"K Fukushima","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"pone.0350106.ref011","doi-asserted-by":"crossref","first-page":"1602503","DOI":"10.1183\/13993003.02503-2016","article-title":"Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype","volume":"50","author":"WJ Koh","year":"2017","journal-title":"Eur Respir J"},{"issue":"4","key":"pone.0350106.ref012","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"DE Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"pone.0350106.ref013","first-page":"1001","article-title":"Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients","volume":"85","author":"T Onodera","year":"1984","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"pone.0350106.ref014","doi-asserted-by":"crossref","first-page":"100601","DOI":"10.1016\/j.nutos.2025.11.008","article-title":"Prognostic nutritional index: a comprehensive review across clinical specialties","volume":"66","author":"N Kudeken","year":"2026","journal-title":"Clinical Nutrition Open Science"},{"issue":"2","key":"pone.0350106.ref015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"EG Brown","year":"1999","journal-title":"Drug Saf"},{"key":"pone.0350106.ref016","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. National Cancer Institute; Published 2017 Nov 27 [cited 2025 Jan 1]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"issue":"3","key":"pone.0350106.ref017","doi-asserted-by":"crossref","first-page":"1800170","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"J van Ingen","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"pone.0350106.ref018","article-title":"Evaluation of Mycobacterium avium complex pulmonary disease treatment completion and adherence to ATS\/IDSA guidelines","volume":"76","author":"JH Ku","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0350106.ref019","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"R Diel","year":"2018","journal-title":"Chest"},{"issue":"1","key":"pone.0350106.ref020","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41598-021-81025-w","article-title":"First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease","volume":"11","author":"K Fukushima","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0350106.ref021","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1513\/AnnalsATS.202412-1307OC","article-title":"Adverse drug reactions during nontuberculous mycobacterial pulmonary disease treatment: a systematic review and meta-analysis","volume":"23","author":"J Kim","year":"2026","journal-title":"Ann Am Thorac Soc"},{"key":"pone.0350106.ref022","unstructured":"National Cancer Institute. The National Cancer Institute Patient Reported Outocmes-Common Terminology Criteria for Adverse Events (PROCTCAE). National Cancer Institute; Published 2023 Nov 5 [cited 2024 Dec 24]. Available from: https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/instrument-pro.html"},{"issue":"9","key":"pone.0350106.ref023","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"E Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"pone.0350106.ref024","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1078155209355848","article-title":"Chemotherapy dose intensity reductions due to adverse drug reactions in an oncology outpatient setting","volume":"16","author":"P Llopis-Salvia","year":"2010","journal-title":"J Oncol Pharm Pract"},{"key":"pone.0350106.ref025","unstructured":"World Health Organization. Active TB drug-safety monitoring and management (aDSM); Published 2015 Aug 11 [cited 2024 Dec 24]. Available from: https:\/\/www.who.int\/publications\/m\/item\/active-tb-drug-safety-monitoring-and-management-(adsm)"},{"issue":"1","key":"pone.0350106.ref026","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s41687-024-00790-0","article-title":"Exploring the factors influencing the health-related quality of life in patients experiencing adverse drug reactions: a cross-sectional study","volume":"8","author":"G Pavan","year":"2024","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"pone.0350106.ref027","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s12890-022-02109-5","article-title":"Nutritional status in female patients with nontuberculous mycobacterial lung disease and its association with disease severity","volume":"22","author":"Y Takayama","year":"2022","journal-title":"BMC Pulm Med"},{"issue":"1","key":"pone.0350106.ref028","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12890-016-0349-3","article-title":"Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease\u00a0: a prospective cohort study","volume":"17","author":"SJ Kim","year":"2017","journal-title":"BMC Pulm Med"},{"issue":"5","key":"pone.0350106.ref029","article-title":"Impact of prognostic nutritional index on outcomes in patients with Mycobacterium avium complex pulmonary disease","volume":"15","author":"SW Moon","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"pone.0350106.ref030","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.21037\/jtd-20-803","article-title":"Prognostic nutritional index as a predictor of mortality in nontuberculous mycobacterial lung disease","volume":"12","author":"Y Hachisu","year":"2020","journal-title":"J Thorac Dis"},{"issue":"1","key":"pone.0350106.ref031","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12931-026-03579-5","article-title":"Association between nutritional status and clinical characteristics in nontuberculous mycobacterial pulmonary disease: preliminary results from the NTM-KOREA cohort","volume":"27","author":"S Yang","year":"2026","journal-title":"Respir Res"},{"key":"pone.0350106.ref032","doi-asserted-by":"crossref","first-page":"1546465","DOI":"10.3389\/fphar.2025.1546465","article-title":"Effect of hypoalbuminemia on drug pharmacokinetics","volume":"16","author":"I Idasiak-Piechocka","year":"2025","journal-title":"Front Pharmacol"},{"issue":"4","key":"pone.0350106.ref033","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1134\/S1990519X2204006X","article-title":"Lymphopenia and mechanisms of T-cell regeneration","volume":"16","author":"EV Saidakova","year":"2022","journal-title":"Cell Tissue Biol"},{"key":"pone.0350106.ref034","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3389\/fimmu.2018.00585","article-title":"Regulatory T-cells: potential regulator of tissue repair and regeneration","volume":"9","author":"J Li","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"pone.0350106.ref035","doi-asserted-by":"crossref","first-page":"1600537","DOI":"10.1183\/13993003.00537-2016","article-title":"Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course","volume":"49","author":"JA Hwang","year":"2017","journal-title":"Eur Respir J"},{"issue":"5","key":"pone.0350106.ref036","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.chest.2021.10.048","article-title":"Impact of time between diagnosis and treatment for nontuberculous mycobacterial pulmonary disease on culture conversion and all-cause mortality","volume":"161","author":"Y Im","year":"2022","journal-title":"Chest"},{"issue":"1","key":"pone.0350106.ref037","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.clinme.2024.100017","article-title":"Non-tuberculous mycobacterial pulmonary disease (NTM-PD): epidemiology, diagnosis and multidisciplinary management","volume":"24","author":"K Kumar","year":"2024","journal-title":"Clin Med (Lond)"},{"key":"pone.0350106.ref038","doi-asserted-by":"crossref","first-page":"100244","DOI":"10.1016\/j.jctube.2021.100244","article-title":"Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease","volume":"24","author":"KM Pennington","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"pone.0350106.ref039","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cardfail.2023.02.011","article-title":"Multidisciplinary care in heart failure services","volume":"29","author":"G Sokos","year":"2023","journal-title":"J Card Fail"},{"issue":"4","key":"pone.0350106.ref040","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1513\/pats.200708-125ET","article-title":"Multidisciplinary care of the patient with chronic obstructive pulmonary disease","volume":"5","author":"AM Kuzma","year":"2008","journal-title":"Proc Am Thorac Soc"},{"issue":"3","key":"pone.0350106.ref041","doi-asserted-by":"crossref","first-page":"00215","DOI":"10.1183\/23120541.00215-2022","article-title":"Multidisciplinary care in chronic airway diseases: the Newcastle model","volume":"8","author":"VM McDonald","year":"2022","journal-title":"ERJ Open Res"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:32:04Z","timestamp":1779903124000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350106"}},"subtitle":[],"editor":[{"given":"Fumihiro","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0350106","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}